Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing neurons by improving mitochondrial quality […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!